{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:05:59Z","timestamp":1782504359677,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clinre.2024.102514","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T16:49:54Z","timestamp":1734022194000},"page":"102514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study"],"prefix":"10.1016","volume":"49","author":[{"given":"Victoire","family":"Dabout","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mineur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine Le","family":"Malicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gallois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Marc","family":"Phelip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicte","family":"Demoustier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Locher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles-Briac","family":"Levach\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Mitry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Brocard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Hassid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Porte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Breysacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Lagasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Val\u00e9ry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2024.102514_bib0001","unstructured":"TNCD | SNFGE.org - Soci\u00e9t\u00e9 savante m\u00e9dicale fran\u00e7aise d'h\u00e9pato-gastroent\u00e9rologie et d'oncologie digestive [Internet]. [cit\u00e9 29 mars 2022]. Disponible sur: https:\/\/www.snfge.org\/tncd."},{"key":"10.1016\/j.clinre.2024.102514_bib0002","unstructured":"Incidence et mortalit\u00e9 des cancers - Les donn\u00e9es sur les cancers [Internet]. [cit\u00e9 10 ao\u00fbt 2022]. Disponible sur: https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Les-donnees-sur-les-cancers\/Incidence-et-mortalite-des-cancers."},{"issue":"1","key":"10.1016\/j.clinre.2024.102514_bib0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.clinre.2024.102514_bib0004","first-page":"259","article-title":"Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics. Results of a German prospective multicentre observational study","volume":"38","author":"Mantke","year":"2012","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"3","key":"10.1016\/j.clinre.2024.102514_bib0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/SLA.0b013e3181b4539b","article-title":"Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients","volume":"250","author":"de Jong","year":"2009","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.clinre.2024.102514_bib0006","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.gcb.2009.02.040","article-title":"Control of pelvic symptoms in patients with rectal cancer and synchronous metastases","volume":"33","author":"Tougeron","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.clinre.2024.102514_bib0007","first-page":"108","article-title":"FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: results of the FFCD 1102 phase II trial","volume":"104","author":"Bachet","year":"2018","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.clinre.2024.102514_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01225","article-title":"Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer","author":"Cremolini","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2024.102514_bib0009","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"issue":"17_suppl","key":"10.1016\/j.clinre.2024.102514_bib0010","doi-asserted-by":"crossref","first-page":"LBA3504","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3504","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial","volume":"41","author":"Conroy","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clinre.2024.102514_bib0011","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/ijc.30805","article-title":"What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients","volume":"141","author":"Ma","year":"2017","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.clinre.2024.102514_bib0012","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.sla.0000257358.56863.ce","article-title":"The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma","volume":"246","author":"Peeters","year":"2007","journal-title":"Ann Surg"},{"issue":"17_suppl","key":"10.1016\/j.clinre.2024.102514_bib0013","doi-asserted-by":"crossref","first-page":"LBA3507","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3507","article-title":"Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases","volume":"40","author":"Rahbari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clinre.2024.102514_bib0014","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2023.41.16_suppl.3517","article-title":"Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG)","volume":"41","author":"Koopman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2024.102514_bib0015","unstructured":"The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus - PubMed [Internet]. [cit\u00e9 6 juin 2022]. Disponible sur: https:\/\/pubmed.ncbi.nlm.nih.gov\/22962059\/."},{"issue":"8","key":"10.1016\/j.clinre.2024.102514_bib0016","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"4","key":"10.1016\/j.clinre.2024.102514_bib0017","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.clinre.2024.102514_bib0018","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1245\/ASO.2006.03.094","article-title":"Treatment with 5-fluorouracil\/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer","volume":"13","author":"Masi","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.clinre.2024.102514_bib0019","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1245\/s10434-015-4460-0","article-title":"Long-term outcomes of conversion hepatectomy for initially unresectable colorectal liver metastases","volume":"23","author":"Maeda","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"17_suppl","key":"10.1016\/j.clinre.2024.102514_bib0020","doi-asserted-by":"crossref","first-page":"LBA3506","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3506","article-title":"FOLFOXIRI + bevacizumab versus FOLFOX\/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and\/or RAS\/BRAFV600E-mutated primary tumor: phase III CAIRO5 study of the Dutch Colorectal Cancer Group","volume":"40","author":"Punt","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clinre.2024.102514_bib0021","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clinre.2024.102514_bib0022","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17","key":"10.1016\/j.clinre.2024.102514_bib0023","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clinre.2024.102514_bib0024","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/annonc\/mdu580","article-title":"Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial","volume":"26","author":"Gruenberger","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clinre.2024.102514_bib0025","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1200\/JCO.2016.34.15_suppl.3512","article-title":"FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: a phase II randomized Study\u2014Prodige 14 \u2013 ACCORD 21 (METHEP-2), a unicancer GI trial","volume":"34","author":"Ychou","year":"2016","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.clinre.2024.102514_bib0026","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.19.01340","article-title":"FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109)","volume":"37","author":"Modest","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"17_suppl","key":"10.1016\/j.clinre.2024.102514_bib0027","doi-asserted-by":"crossref","first-page":"LBA3505","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3505","article-title":"Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI\/PAN) versus mFOLFOX6\/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): results of the phase III randomized TRIPLETE study by GONO","volume":"40","author":"Cremolini","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2024.102514_bib0028","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"15","key":"10.1016\/j.clinre.2024.102514_bib0029","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clinre.2024.102514_bib0030","first-page":"87","article-title":"The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials","volume":"70","author":"Holch","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"12","key":"10.1016\/j.clinre.2024.102514_bib0031","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9617","key":"10.1016\/j.clinre.2024.102514_bib0032","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","article-title":"Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial","volume":"371","author":"Nordlinger","year":"2008","journal-title":"Lancet Lond Engl"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124002353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740124002353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:19:19Z","timestamp":1737332359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740124002353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2210740124002353"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102514","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2024.102514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102514"}}